Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data

Journal of Cystic Fibrosis

Volumn 14, Issue 2, 2015, Pages 194-202

  Van der Ploeg, C P B ^a   van den Akker van Marle, M E ^b,k   Vernooij van Langen, A M M ^c,d,f   Elvers, L H ^d,g   Gille, J J P ^e,i   Verkerk, P H ^a   Dankert Roelse, J E ^c,f   Loeber, J G ^g   Triepels, R H ^h   van der Pal, S M ^a   Dompeling, E ^a   Pals, G ^j   Gulmans, V A M ^l   Oey Spauwen, M J W ^m   Wijnands, Y H H M ^m   Castricum, L M ^g   Arets, H G M ⁿ   van der Ent, C K ⁿ   Tiddens, H A W M ^o   de Rijke, Y B ^o   Yntema, J B ^p   more..

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Atrium Medical Centre   (United States)

^g RIVM   (United States)

^h St Elisabeth Hospital   (United States)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j Department of Internal Medicine   (United States)

^k VU Medical Centre   (United States)

^l LUMC   (United States)

^m CR Foundation   (United States)

ⁿ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Cost effectiveness; Cystic fibrosis; Newborn screening

Indexed keywords

ARTICLE; CHILDHOOD MORTALITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; EARLY DIAGNOSIS; GENETIC COUNSELING; HUMAN; IMMUNOREACTIVE TRYPSINOGEN DNA; IMMUNOREACTIVE TRYPSINOGEN DNA SEQUENCING; IMMUNOREACTIVE TRYPSINOGEN PANCREATITIS ASSOCIATED PROTEIN DNA SEQUENCING; IMMUNOREACTIVE TRYPSINOGEN PANCREATITIS ASSOCIATED PROTEIN TESTING; MAJOR CLINICAL STUDY; NETHERLANDS; NEWBORN; NEWBORN DISEASE; NEWBORN SCREENING; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SWEAT TEST; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; GENETIC SCREENING; GENETICS; MUTATION; ORGANIZATION AND MANAGEMENT; PROCEDURES;

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LECTIN; PANCREATITIS-ASSOCIATED PROTEIN; TRYPSINOGEN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DECISION SUPPORT TECHNIQUES; GENETIC TESTING; HUMANS; INFANT, NEWBORN; LECTINS, C-TYPE; MUTATION; NEONATAL SCREENING; NETHERLANDS; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN;

EID: 84924286082     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.08.007     Document Type: Article

References (30)

1. van den Akker-van Marle M.E., Dankert H.M., Verkerk P.H., et al. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 2006, 118:896-905.
2. Sarles J., Berthezene P., Le Louarn C., et al. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 2005, 147:302-305.
3. Mérelle M.E., Scheffer H., de Jong D., et al. Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis. Acta Paediatr 2006, 95:1424-1428.
4. Vernooij-van Langen A.M., Loeber J.G., Elvers B., et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax 2012, 67:289-295.
5. Slieker M.G., Uiterwaal C.S., Sinaasappel M., et al. Birth prevalence and survival in cystic fibrosis: a national cohort study in the Netherlands. Chest 2005, 128:2309-2315.
6. Gold M.R., Siegel J.E., Russell L.B., et al. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York.
7. Frederiksen B., Lanng S., Koch C., et al. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996, 21:153-158.
8. Grosse S.D., Boyle C.A., Botkin J.R., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004, 53(RR-13):1-36.
9. Simpson N., Anderson R., Sassi F., et al. The cost-effectiveness of neonatal screening Cystic Fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc 2005, 3:8.
10. Ranieri E., Lewis B.D., Gerace R.L., et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ 1994, 308:1469-1472.
11. Mayell S.J., Munck A., Craig J.V., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009, 8:71-78.
12. Munck A., Dhondt J.L., Sahler C., et al. Implementation of the French nationwide cystic fibrosis newborn screening program. J Pediatr 2008, 153:228-233.
13. Sarles J., Barthellemy S., Férec C., et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999, 80:F118-F122.
14. Sommerburg O., Krulisova V., Hammermann J., Lindner M., Stahl M., Muckenthaler M., et al. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. J Cyst Fibros 2014 Jan, 13(1):15-23. 10.1016/j.jcf.2013.06.003.
15. Keiles S.B., Kilbourne K., Kharrazi M., et al. 100% CFTR mutation detection in a group of patients affected with CF using the Ambry test: CF amplified. Pediatr Pulmonol 2005, (Suppl. 28):252.
16. Dankert-Roelse J.E., Mérelle M.E. Review of outcomes of neonatal screening for cystic fibrosis versus non-screening in Europe. J Pediatr 2005, 147(3 Suppl.):S15-S20.
17. Grosse S.D., Rosenfeld M., Devine O.J., et al. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr 2006, 149:362-366.
18. Vernooij-van Langen A.M.M., Reijntjens S., van der Pal S.M., et al. To know or not to know, disclosure of a newborn carrier screening test result for cystic fibrosis. Eur J Med Genet 2013, 56:192-196.
19. Wheeler P.G., Smith R., Dorkin H., et al. Genetic counseling after implementation of statewide cystic fibrosis newborn screening: two years' experience in one medical center. Genet Med 2001, 3:411-415.
20. Mischler E.H., Wilfond B.S., Fost N., et al. Cystic fibrosis newborn screening: impact on reproductive behavior and implications for genetic counseling. Pediatrics 1998, 102:44-52.
21. Ciske D.J., Haavisto A., Laxova A., et al. Genetic counseling and neonatal screening for cystic fibrosis: an assessment of the communication process. Pediatrics 2001, 107(4):699-705.
22. Oostenbrink J.B., Bouwmans C.A.M., Koopmanschap M.A., et al. Handbook for costing research, methods and guideline prices for economic evaluations in health 2004, [In Dutch], Health Care Insurance Board, Amstelveen.
23. Harrington J., Southern K.W., Barton P., et al. The impact of a national newborn screening programme on sweat testing services. J Cyst Fibros 2012, 11(Supplement 1):S49. [abstract].
24. Kerem E., Conway S., Elborn S., et al. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 2005, 4:7-26.
25. Wildhagen M.F. Cost and effects of genetic screening with application to cystic fibrosis and fragile X syndrome 1999, [thesis], Erasmus University, Rotterdam.
26. Sims E.J., Mugford M., Clark A., et al. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet 2007, 369(9568):1187-1195. [Erratum in: Lancet 2007;370(9581):28].
27. Wells J., Rosenberg M., Hoffman G., et al. A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. Pediatrics 2012, 129(2):e339-e347. 10.1542/peds.2011-0096.
28. Nshimyumukiza L., et al. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study. J Cyst Fibros 2014, 13:267-274.
29. Tluczek A., Becker T., Laxova A., et al. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest 2011, 140(1):170-177.
30. Dijk F.N., McKay K., Barzi F., et al. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child 2011, 96:1118-1123.